Xavier Filella Pla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/96418/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality. Hepatology, 1998, 27, 1227-1232.	7.3	387
2	Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. European Respiratory Journal, 1999, 14, 1015-1022.	6.7	318
3	SERUM CYTOKINES (IL-6, TNF-α, IL-1Î ² AND IFN-Î ³) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWE SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY. Rheumatology, 1994, 33, 927-931.	EN 1.9	299
4	Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis. Tumor Biology, 2003, 24, 209-218.	1.8	233
5	Bronchial Inflammation and Colonization in Patients with Clinically Stable Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1628-1632.	5.6	223
6	Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax, 2009, 64, 587-591.	5.6	199
7	Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases. Clinical Chemistry, 2011, 57, 1534-1544.	3.2	167
8	Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. Critical Care Medicine, 1999, 27, 1745-1753.	0.9	164
9	Acute phase response in laparoscopic and open colectomy in colon cancer. Diseases of the Colon and Rectum, 2001, 44, 638-646.	1.3	163
10	Markers of treatment failure in hospitalised community acquired pneumonia. Thorax, 2008, 63, 447-452.	5.6	156
11	Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. European Respiratory Journal, 1999, 14, 218.	6.7	153
12	Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. Clinical Cancer Research, 2006, 12, 5578-5586.	7.0	147
13	Increased tumour necrosis factorâ€Î± plasma levels during moderate-intensity exercise in COPD patients. European Respiratory Journal, 2003, 21, 789-794.	6.7	143
14	Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis. Prostate, 2017, 77, 573-583.	2.3	141
15	Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 427-437.	5.6	139
16	HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biology, 2011, 32, 1087-1095.	1.8	133
17	Causes and predictors of nonresponse to treatment of intensive care unit–acquired pneumonia*. Critical Care Medicine, 2004, 32, 938-945.	0.9	132
18	Evaluation of [â^'2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clinical Chemistry and Laboratory Medicine, 2013, 51, 729-739.	2.3	129

#	Article	IF	CITATIONS
19	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis and Rheumatism, 2002, 47, 29-35.	6.7	127
20	Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood, 2010, 116, 4771-4776.	1.4	126
21	Smoldering multiple myeloma: natural history and recognition of an evolving type. British Journal of Haematology, 2003, 123, 631-636.	2.5	119
22	ProGRP: a new biomarker for small cell lung cancer. Clinical Biochemistry, 2004, 37, 505-511.	1.9	118
23	Neutrophil Gelatinaseâ€Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70, 319-333.	7.3	114
24	Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. American Heart Journal, 2002, 144, 811-817.	2.7	112
25	Prognostic value of serum cytokines in patients with congestive heart failure. Journal of Heart and Lung Transplantation, 2000, 19, 419-425.	0.6	109
26	Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Research and Treatment, 1995, 36, 41-48.	2.5	108
27	Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biology, 2008, 29, 371-380.	1.8	107
28	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Research and Treatment, 1998, 51, 109-119.	2.5	104
29	Prognostic Value of CA 19.9 Levels in Colorectal Cancer. Annals of Surgery, 1992, 216, 55-59.	4.2	101
30	Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica, 2004, 89, 832-6.	3.5	100
31	Value of postoperative surveillance after radical surgery for colorectal cancer. Diseases of the Colon and Rectum, 1998, 41, 714-723.	1.3	99
32	Carcinoembryonic Antigen in Staging and Follow-Up of Patients with Solid Tumors. Tumor Biology, 1995, 16, 32-41.	1.8	97
33	Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology. Tumor Biology, 2009, 30, 121-129.	1.8	94
34	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology, 2014, 147, 628-636.e1.	1.3	94
35	Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. International Journal of Molecular Sciences, 2016, 17, 1784.	4.1	93
36	miRNAs as novel biomarkers in the management of prostate cancer. Clinical Chemistry and Laboratory Medicine, 2017, 55, 715-736.	2.3	89

#	Article	IF	CITATIONS
37	Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone, 2013, 57, 272-276.	2.9	86
38	Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1998, 82, 688-690.	1.6	82
39	Pulmonary Infiltrates in Patients Receiving Long-term Glucocorticoid Treatment*. Chest, 2003, 123, 488-498.	0.8	80
40	Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. Mayo Clinic Proceedings, 2007, 82, 428-434.	3.0	76
41	Increased plasma concentrations of tumour markers in the absence of neoplasia. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1605-20.	2.3	76
42	Cytokine-induced inflammation and long-term stroke functional outcome. Journal of the Neurological Sciences, 1999, 162, 185-188.	0.6	72
43	Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. European Respiratory Journal, 2011, 37, 393-399.	6.7	71
44	Emerging biomarkers in the diagnosis of prostate cancer. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 83-94.	0.7	71
45	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clinical Chemistry, 2010, 56, 1148-1157.	3.2	70
46	Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	69
47	Stability in community-acquired pneumonia: one step forward with markers?. Thorax, 2009, 64, 987-992.	5.6	67
48	Tumor Markers in Chronic Renal Failure and Hemodialysis Patients. Nephron, 1991, 57, 183-186.	1.8	66
49	Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Research, 2005, 25, 1773-8.	1.1	66
50	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. British Journal of Cancer, 1996, 74, 1126-1131.	6.4	64
51	Serum Levels of C-erbB-2 (HER-2/neu) in Patients with Malignant and Non-Malignant Diseases. Tumor Biology, 1997, 18, 188-196.	1.8	63
52	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biology, 2010, 31, 171-180.	1.8	61
53	Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood, 2009, 114, 4954-4956.	1.4	60
54	Clinical and inflammatory markers in amniotic fluid as predictors of adverse outcomes in preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology, 2011, 205, 126.e1-126.e8.	1.3	60

4

#	Article	IF	CITATIONS
55	Study of a New Tumor Marker, CYFRA21-1, in Malignant and Nonmalignant Diseases. Tumor Biology, 1994, 15, 318-325.	1.8	59
56	Serum osteoprotegerin and its ligand in Paget's disease of bone: Relationship to disease activity and effect of treatment with bisphosphonates. Arthritis and Rheumatism, 2003, 48, 824-828.	6.7	57
57	Peritoneal response to a septic challenge. Surgical Endoscopy and Other Interventional Techniques, 1999, 13, 792-796.	2.4	56
58	S-100 Protein Serum Levels in Patients with Benign and Malignant Diseases: False-Positive Results Related to Liver and Renal Function. Tumor Biology, 2002, 23, 39-44.	1.8	56
59	Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate, 2000, 44, 271-274.	2.3	54
60	Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer Journal of Clinical Oncology, 1998, 16, 1036-1039.	1.6	53
61	Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumor Biology, 2012, 33, 463-474.	1.8	52
62	Nuclear factorâ€kappa B and interleukinâ€6 related docetaxel resistance in castrationâ€resistant prostate cancer. Prostate, 2013, 73, 512-521.	2.3	52
63	Acute Phase is the Only Significantly Reduced Component of the Injury Response after Laparoscopic Cholecystectomy. World Journal of Surgery, 1996, 20, 528-534.	1.6	49
64	PCA3 in the detection and management of early prostate cancer. Tumor Biology, 2013, 34, 1337-1347.	1.8	48
65	Predictive value of combined amniotic fluid proteomic biomarkers and interleukin-6 in preterm labor with intact membranes. American Journal of Obstetrics and Gynecology, 2009, 200, 499.e1-499.e6.	1.3	47
66	Evaluation of a new ultrasensitive assay for cardiac troponin I. Clinical Biochemistry, 2007, 40, 1406-1413.	1.9	45
67	Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. Tumor Biology, 2004, 25, 56-61.	1.8	44
68	Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1347-55.	2.3	43
69	Cyfra 21–1 in Lung Cancer: Comparison with Cea, Ca 125, Scc and Nse Serum Levels. International Journal of Biological Markers, 1994, 9, 96-101.	1.8	42
70	Effect of proinflammatory cytokines (IL-6, TNF-α, IL-1β) on hemodynamic performance during orthotopic liver transplantation. Transplantation Proceedings, 2003, 35, 1884-1887.	0.6	42
71	CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumor Biology, 2012, 33, 799-807.	1.8	42
72	Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica, 2013, 98, 1142-1146.	3.5	42

#	Article	IF	CITATIONS
73	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine, 2008, 41, 244-253.	3.2	41
74	Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica, 2011, 96, 171-173.	3.5	38
75	Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs*. Critical Care Medicine, 2012, 40, 162-168.	0.9	37
76	Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. Seminars in Arthritis and Rheumatism, 2002, 32, 56-63.	3.4	36
77	Prospective Evaluation of Squamous Cell Carcinoma <i></i> and Carcinoembryonic Antigen as Prognostic Factors in Patients with Cervical Cancer. Tumor Biology, 2003, 24, 156-164.	1.8	36
78	Clinical usefulness of free PSA fraction as an indicator of prostate cancer. International Journal of Cancer, 1995, 63, 780-784.	5.1	35
79	Emerging biomarkers in the detection and prognosis of prostate cancer. Clinical Chemistry and Laboratory Medicine, 2015, 53, 963-73.	2.3	35
80	High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Research, 2017, 59, 20-25.	0.8	35
81	Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency. Anticancer Research, 2018, 38, 5883-5888.	1.1	35
82	Use of CA 19-9 in the Early Detection of Recurrences in Colorectal Cancer: Comparison with CEA. Tumor Biology, 1994, 15, 1-6.	1.8	34
83	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	3.2	34
84	Prognostic Significance of SCC Antigen in the Serum of Patients with Head and Neck Cancer. Tumor Biology, 1996, 17, 81-89.	1.8	32
85	Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. Journal of Bone and Mineral Metabolism, 2004, 22, 254-259.	2.7	32
86	A Prospective Study of Tumor Markers CA 125 and CA 19.9 in Patients with Epithelial Ovarian Carcinomas. Tumor Biology, 1992, 13, 278-286.	1.8	31
87	CA 125 in Biological Fluids. International Journal of Biological Markers, 1998, 13, 224-230.	1.8	31
88	Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. , 2000, 42, 181-185.		31
89	Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. British Journal of Haematology, 2004, 126, 372-376.	2.5	31
90	Prostate cancer screening: guidelines review and laboratory issues. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1474-1487.	2.3	31

#	Article	IF	CITATIONS
91	Cervical length and gestational age at admission as predictors of intraâ€amniotic inflammation in preterm labor with intact membranes. Ultrasound in Obstetrics and Gynecology, 2009, 34, 441-447.	1.7	29
92	Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous StemÂCell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1076-1079.	2.0	29
93	Effect of Recent Spinal Cord Injury on Wnt Signaling Antagonists (Sclerostin and Dkk-1) and Their Relationship With Bone Loss. A 12-Month Prospective Study. Journal of Bone and Mineral Research, 2015, 30, 1014-1021.	2.8	29
94	The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10î¼g/L. Clinica Chimica Acta, 2014, 436, 303-307.	1.1	28
95	Circulating levels of HER-2/neu oncoprotein in breast cancer. Clinical Chemistry and Laboratory Medicine, 2012, 50, 5-21.	2.3	27
96	Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 261-267.	1.2	26
97	Reference intervals for bone turnover markers in Spanish premenopausal women. Clinical Chemistry and Laboratory Medicine, 2016, 54, 293-303.	2.3	26
98	Relationship of p53 with other Oncogenes, Cytokines and Systemic Lupus Erythematosus Activity. Tumor Biology, 2003, 24, 185-188.	1.8	25
99	Prospective Study of Individualized or High Fixed Doses of Vitamin D Supplementation After Bariatric Surgery. Obesity Surgery, 2015, 25, 470-476.	2.1	25
100	REDUCED ACTIVITY OF SERUM CREATINE KINASE IN RHEUMATOID ARTHRITIS: A PHENOMENON LINKED TO THE INFLAMMATORY RESPONSE. Rheumatology, 1994, 33, 231-234.	1.9	24
101	Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2006, 37, 499-502.	2.4	24
102	Variability of assay methods for total and free PSA after WHO standardization. Tumor Biology, 2014, 35, 1867-1873.	1.8	24
103	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. Journal of Infectious Diseases, 1999, 179, 475-483.	4.0	23
104	Cytokine-Release Patterns in Elderly Patients with Systemic Inflammatory Response Syndrome. Gerontology, 2007, 53, 239-244.	2.8	23
105	Impact of Ultrasensitive Cardiac Troponin I Dynamic Changes in the New Universal Definition of Myocardial Infarction. American Journal of Clinical Pathology, 2008, 130, 964-968.	0.7	23
106	Detection of nonprostatic PSA in serum and nonserum samples from women. , 1996, 68, 424-427.		22
107	Interleukin-4, interleukin-10, and granulocyte-macrophage colony stimulating factor in second-trimester serum from women with preeclampsia. Obstetrics and Gynecology, 1998, 92, 849-853.	2.4	22
108	Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clinical Laboratory, 2003, 49, 15-24.	0.5	22

#	Article	IF	CITATIONS
109	Tag-72, CA 19.9 and CEA as Tumor Markers in Gastric Cancer. Acta OncolÃ ³ gica, 1994, 33, 747-751.	1.8	20
110	Inflammatory Responses in Blood Samples of Human Immunodeficiency Virus-Infected Patients with Pulmonary Infections. Vaccine Journal, 2004, 11, 608-614.	3.1	20
111	Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis. Pathology and Oncology Research, 2019, 25, 1445-1456.	1.9	20
112	Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Annals of Oncology, 2008, 19, 269-275.	1.2	19
113	Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study. Osteoporosis International, 2017, 28, 2457-2464.	3.1	19
114	Novel Biomarkers for Prostate Cancer Detection and Prognosis. Advances in Experimental Medicine and Biology, 2018, 1095, 15-39.	1.6	19
115	Evaluation of Inflammatory and Renal-Injury Markers in Women Treated with Antibiotics for Acute Pyelonephritis Caused by Escherichia coli. Vaccine Journal, 2004, 11, 142-146.	2.6	18
116	Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients. Thorax, 2004, 59, 1081-1088.	5.6	18
117	Th1/Th2 Cytokine Release Pattern During In Vivo Cytomegalovirus Disease in Solid Organ Transplantation. Transplantation Proceedings, 2007, 39, 2233-2235.	0.6	17
118	Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e71-e77.	0.4	17
119	Prostate-specific antigen detection by ultrasensitive assay in samples from women. , 1996, 29, 311-316.		16
120	Clinical evaluation of free PSA/Total PSA (Prostate-specific Antigen) ratio in the diagnosis of prostate cancer. European Journal of Cancer, 1997, 33, 1226-1229.	2.8	16
121	Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study. European Journal of Cancer, 1996, 32, 1125-1128.	2.8	15
122	Evaluation of the Analytical and Clinical Performance of the Elecsys® CA 15-3 Immunoassay. Clinical Chemistry, 2001, 47, 2162-2164.	3.2	13
123	Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta, 2014, 435, 53-58.	1.1	13
124	Free and Total PSA in the Diagnosis of Prostate Cancer. Tumor Biology, 1997, 18, 332-340.	1.8	12
125	Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. Clinica Chimica Acta, 2020, 501, 174-178.	1.1	11
126	Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer. Tumor Biology, 1996, 17, 20-26.	1.8	10

#	Article	IF	CITATIONS
127	Serum levels of β2-microglobulin, neopterin, TNF-α and soluble receptors of TNF-α and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection. Clinical Microbiology and Infection, 1998, 4, 4-10.	6.0	10
128	Systemic inflammatory response after bronchoalveolar lavage in critically ill patients. European Respiratory Journal, 2001, 17, 274-280.	6.7	10
129	Inflammatory impact of NOTES peritoneoscopy is not different from that of laparoscopy: a randomized comparative study in a survival porcine model. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 374-380.	2.4	10
130	Utility of proGRP as a tumor marker in the medullary thyroid carcinoma. Clinical Chemistry and Laboratory Medicine, 2017, 55, 441-446.	2.3	10
131	Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. Blood Purification, 2019, 48, 106-114.	1.8	10
132	IMPAIRED PRODUCTION OF INTERLEUKIN 6 AND TUMOUR NECROSIS FACTOR \hat{I}_{\pm} IN WHOLE BLOOD CELL CULTURES OF PATIENTS WITH MULTIPLE MYELOMA. Cytokine, 1998, 10, 993-996.	3.2	9
133	Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms. Urology, 2004, 63, 1100-1103.	1.0	9
134	Active surveillance in prostate cancer: the need to standardize. Tumor Biology, 2011, 32, 839-843.	1.8	9
135	Concordance between direct and indirect measurements of free 25-OH vitamin D. Clinica Chimica Acta, 2017, 475, 169-171.	1.1	9
136	Evaluation of CD30 as a marker for Th2 lymphocytes in bronchoalveolar lavage in interstitial lung diseases. Respiratory Medicine, 2000, 94, 345-349.	2.9	8
137	Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. Journal of Clinical Laboratory Analysis, 2005, 19, 167-171.	2.1	8
138	Value of PHI and PHID in the detection of intermediate- and high-risk prostate cancer. Clinica Chimica Acta, 2022, 531, 277-282.	1.1	8
139	UNDETECTABLE PROSTATE SPECIFIC ANTIGEN IN DISSEMINATED PROSTATE CANCER. Journal of Urology, 2001, 166, 993-993.	0.4	7
140	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 387-389.	2.5	7
141	High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. Leukemia Research, 2020, 94, 106371.	0.8	7
142	Influence of AFP, CEA and PSA on the in vitro Production of Cytokines. Tumor Biology, 2001, 22, 67-71.	1.8	6
143	Analytical verification and method comparison of the ADVIA Centaur® Intact Parathyroid Hormone assay. Clinical Biochemistry, 2017, 50, 1222-1227.	1.9	6
144	The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplantation, 2017, 52, 415-422.	2.4	6

#	Article	IF	CITATIONS
145	Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern. Anticancer Research, 2019, 39, 1079-1083.	1.1	6
146	Study of Biocompatibility of Membranes in Online Hemodiafiltration. Blood Purification, 2020, 49, 400-408.	1.8	6
147	Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation. Journal of Vascular Access, 2021, 22, 370-379.	0.9	6
148	Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer. Anticancer Research, 2007, 27, 607-10.	1.1	6
149	Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer. Urology, 2003, 62, 243-248.	1.0	5
150	Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Annals of Hematology, 2014, 93, 107-111.	1.8	5
151	Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?. Clinical Genitourinary Cancer, 2015, 13, 499-504.	1.9	5
152	Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone. Bone, 2019, 124, 132-136.	2.9	5
153	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. RMD Open, 2020, 6, e001355.	3.8	5
154	A Rapid Amniotic Fluid Interleukin-6 Assessment for the Identification of Intra-Amniotic Inflammation in Women with Preterm Labor and Intact Membranes. Fetal Diagnosis and Therapy, 2021, 48, 327-332.	1.4	4
155	Multicentre Clinical Evaluation of the COBAS CORE CEA, CA 125 II and PSA Tumor Marker Assays. International Journal of Biological Markers, 1996, 11, 40-45.	1.8	3
156	Evaluation of a Multivariate Prostate-Specific Antigen and Percentage of Free Prostate-Specific Antigen Logistic Regression Model in the Diagnosis of Prostate Cancer. Tumor Biology, 1999, 20, 312-318.	1.8	3
157	Hacia un cribado personalizado del cáncer de próstata. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	3
158	Valor de las citocinas proinflamatorias como factor de predicción de sepsis y mortalidad en el anciano con fiebre. Medicina ClÃnica, 2003, 121, 361-366.	0.6	3
159	Re: Alberto Briganti, Michael L. Blute, James H. Eastham, et al. Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol 2009;55:1251–65. European Urology, 2009, 56, e53.	1.9	2
160	Significado clÃnico del aumento de los valores séricos de FGF-23 en la displasia fibrosa. Medicina ClÃnica, 2018, 151, 65-67.	0.6	2
161	Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases. Clinical Biochemistry, 2020, 76, 42-44.	1.9	2
162	AntÃgeno prostático especÃfico y sus fracciones en el diagnóstico del cáncer de próstata. Medicina ClÃnica, 2004, 122, 241-244.	0.6	2

#	Article	IF	CITATIONS
163	Complexed prostate-specific antigen for the detection of prostate cancer. Anticancer Research, 2004, 24, 4181-5.	1.1	2
164	Calcitriol-Mediated Hypercalcaemia and Increased Interleukins in a Patient with Sarcoid Myopathy. Clinical Rheumatology, 1999, 18, 488-491.	2.2	1
165	Association between anatomopathologic graft disorders during reperfusion and vena cava slL-2r in orthotopic liver transplantation. Transplantation Proceedings, 2003, 35, 1880-1883.	0.6	1
166	Automated measurement of 25-OH Vitamin D on the LUMIPULSE®C1200: analytical verification and method comparison. British Journal of Biomedical Science, 2016, 73, 104-109.	1.3	1
167	Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia. Medicina ClÃnica (English) Tj ETQq1 1	8.28431	4 ₁ rgBT /Ove
168	Towards personalized prostate cancer screening. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	1
169	117: Intra-amniotic inflammation in preterm labor with intact membranes as a marker of adverse perinatal outcomes. American Journal of Obstetrics and Gynecology, 2007, 197, S46.	1.3	0
170	Cytokine Systemic Pattern And Causal Microorganism In Community Acquired Pneumonia. , 2010, , .		0
171	Response: Free light chain assay and stringent complete remission in multiple myeloma: more questions than answers. Blood, 2010, 115, 3414-3415.	1.4	0
172	FP576LOCKING SOLUTIONS IMPACT ON BIOFILM FORMATION IN TUNNELED HEMODIALYSIS CATHETERS AND ACTIVATION OF THE INFLAMMATORY RESPONSE. Nephrology Dialysis Transplantation, 2018, 33, i235-i235.	0.7	0
173	SP469STUDY OF BIOCOMPATIBILITY OF MEMBRANES IN HEMODIAFILTRACIÓN ON-LINE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
174	GuÃas de práctica clÃnica: oportunidad para visibilizar la importancia de la medicina del laboratorio. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 441-450.	0.2	0
175	An opportunity to emphasize the relevance of laboratory medicine. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 432-440.	0.2	0
176	Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution. Blood, 2013, 122, 3132-3132.	1.4	0
177	Evaluación del ensayo enhaced estradiol (eE2) en el analizador Atellica IM 1600 de Siemens. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	0
178	Performance evaluation of Siemens Atellica enhanced estradiol assay. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.2	0
179	Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 588-595.	1.7	0